MicroPort ® Medical Science Co., Ltd. recently announced that its subsidiary, Shanghai MicroPort Investment Holdings Co., Ltd. (hereinafter referred to as "Micro Venture ®"), signed a relevant agreement ® with Shanghai Huabo Information Service Co., Ltd. and Shanghai Fengjun Enterprise Management Partnership (Limited Partnership) to acquire 100% of the equity of Shanghai Huanbo Digital Technology Co., Ltd. (hereinafter referred to as "Huanbo") held by the other party for a total consideration of not more than RMB650 million, and then own all the property rights of Huanbo Science and Technology Park.
It is reported that Huanbo Science and Technology Park is located in the core area of Shanghai Zhangjiang Science City, the national-level Shanghai biomedical science and technology industry base - Zhangjiang Biomedical Base, covering an area of about 30,000 square meters and a total construction area of about 70,000 square meters. The park property will be mainly used for the construction of the new material and pharmaceutical equipment miracle point innovation center to which MicroPort ® Investment belongs, and it is also one of the research and development bases of Fujian Kerui Pharmaceutical Co., Ltd., which is recently acquired by MicroPort ®.
According to Dr. Jiang Hongyan, vice president of micro-invasive ® R&D technical support and sharing platform, the newly established new materials and pharmaceutical device miracle point innovation center will be the office, R&D and production base of micro-invasive ® layout of emerging businesses such as biological new materials and regenerative medicine.
The biomaterials platform will develop basic medical materials for the clinical needs of biomedicine and medical devices to solve problems such as precise sustained release and long-term biocompatibility of materials; the regenerative medicine platform will combine innovative technologies in the field of tissue engineering and regenerative medicine to study and solve urgent problems in the repair of bone and cartilage tissue, skin tissue, nerve tissue, oral cavity and other tissues. Pharmaceutical and device combination products have the 'potential' to make treatment safer, more effective, more convenient or more comfortable for patients to use, and can effectively improve the effectiveness of the original single product drug or device.
Innovation is one of the core values of MicroPort ®. MicroPort said that the acquisition of Huanbo Science and Technology Park property will, to a certain extent, alleviate the increasingly serious lack of physical space for innovation and industrialization commonly faced by all business segments of the Group; at the same time, MicroPort ® will continue to focus on independent innovation.
Column Editor-in-Chief Xu Sufei
Editor-in-charge Deng Qingyuan
Infographic
![At the age of 87, Ye Jianying was critically ill, and the Party Central Committee urgently dispatched Zhong Nanshan to help: a miracle in the history of medical treatment was born[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)